exisulind

A study which was funded by Cell Pathways Inc., developer of the drug Exisulind, suggest that Exisulind may delay disease progression in men with recurrent prostate cancer according to Dr. Erik Goluboff, Assistant Professor of Urology at Columbia University College of Physicians & Surgeons, Director of Urology at The Allen Pavilion of New York-Presbyterian Hospital, [...]